Mountain Valley MD (MVMD) AI Stock Analysis

• Market Cap: C$5.29M
• Dividend Yield: N/A
• Average Volume (3M): 205.59K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.34
• Revenue Growth: -46.59%
• EPS Growth: 8.26%
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): >-0.01
• Shares Outstanding: 352,354,950
• 10 Day Avg. Volume: 152,980
• 30 Day Avg. Volume: 205,595
• PEG Ratio: 0.14
• Price to Book (P/B): 3.44
• Price to Sales (P/S): 177.77
• P/FCF Ratio: -2.23
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 41 Neutral
• Price Target: C$0.01 ▼(-50.00% Downside)

The score is primarily held down by weak financial performance (minimal revenue, large losses, and persistent cash burn with a diminished equity base), compounded by bearish technicals (trading below all major moving averages with negative MACD). Valuation provides limited offset because the company is loss-making (negative P/E) and no dividend yield is available.

Positive Factors

Low leverage / near-zero debt

Near-zero reported debt materially reduces interest burden and financial distress risk over the medium term. With minimal leverage, the company has greater optionality to prioritize R&D or business development over debt servicing, preserving strategic flexibility while it pursues commercialization.

Improving gross profit / unit economics

A return to positive gross profit suggests product-level margins can cover direct costs, a prerequisite for scalable profitability. If sustained, this improvement supports future operating leverage: reduced need for price support and a clearer path to narrowing operating losses as fixed costs are managed.

Industry exposure: specialty & generic drugs

Positioning in specialty and generic pharmaceuticals offers structural demand and persistent market need. Regulatory barriers and manufacturing requirements can create entry frictions, enabling established players to capture steady revenue streams if the company can stabilize operations and commercial execution.

Negative Factors

Persistent negative cash generation

Consistent negative operating and free cash flow erodes runway and forces repeated external financing. Over months, this limits ability to fund R&D, scale commercialization, or withstand setbacks without dilutive equity raises, constraining long-term strategic options and investor returns.

Eroding equity cushion / capital base

A steep decline in shareholders' equity reflects cumulative losses and weak capital retention, leaving a thin buffer for operational shocks. This degradation increases the probability of future dilution, reduces credibility with lenders/partners, and impairs the firm's ability to pursue sustained growth investments.

Minimal, declining and volatile revenue

Extremely small and falling revenue undermines scale economies and market validation. With limited sales, fixed operating costs dominate, making margin improvement difficult and heightening reliance on financing. Persistent top-line weakness challenges long-term viability absent clear commercial traction.

Mountain Valley MD Business Overview & Revenue Model

Company Description

Mountain Valley MD Holdings Inc., through its subsidiary, Mountain Valley MD Inc., operates as a health and wellness company. The company engages in the implementation and licensing of its technologies to pharmaceutical, vaccine, and nutraceutical third parties. It offers Quicksome oral drug formulation and delivery technologies; Quicksol solubility formulation technology; and dose sparing adjuvant. In addition, the company is developing IM032 for the treatment of male beagle dogs for comparing intramuscular and subcutaneous dosing. Mountain Valley MD Holdings Inc. is headquartered in Concord, Canada.

How the Company Makes Money

Mountain Valley MD makes money through the commercialization of its proprietary health solutions. The company generates revenue from the sale of its pharmaceutical and nutraceutical products, leveraging its unique delivery systems and formulations. Additionally, MVMD may establish partnerships with other pharmaceutical firms to co-develop or license its technologies, which can provide significant revenue streams through licensing fees, royalties, and milestone payments. The company's focus on scalable and cost-effective solutions contributes to its earnings potential in both emerging and established markets.

Mountain Valley MD Financial Statement Overview

Summary

Financials reflect an early-stage profile with very small, declining revenue (~C$49k in 2025), large net losses (~C$7.5M in 2025), and persistent negative operating/free cash flow (~-C$3.9M in 2025). Low/near-zero debt is a positive, but equity has eroded sharply (to ~C$2.5M in 2025), increasing dilution/financing risk.

Income Statement

Revenue remains very small and volatile, with 2025 annual revenue down ~85% year over year (C$49k vs. C$60k). Profitability is materially weak: the company is deeply loss-making with negative operating profit and a net loss of ~C$7.5M in 2025, translating to extremely negative net margins. A positive point is that 2025 gross profit is positive (unlike 2024), but overall the income statement profile reflects an early-stage business with heavy operating spend relative to revenue and no clear earnings traction yet.

Balance Sheet

Leverage is a clear strength: reported total debt is effectively zero in 2024–2025 and very low historically, which reduces financial risk. However, the balance sheet has weakened meaningfully as equity declined from ~C$30.5M (2021) to ~C$2.5M (2025), consistent with ongoing losses eroding the capital base; returns on equity are strongly negative. Overall, low debt helps, but the shrinking equity cushion is a key concern.

Cash Flow

Cash generation is weak, with operating cash flow negative every year shown and worsening to about -C$3.9M in 2025. Free cash flow is also consistently negative (about -C$3.9M in 2025), indicating ongoing cash burn and continued reliance on external funding over time. While cash burn did not spike dramatically versus 2024, the persistent negative cash profile and lack of self-funding capacity are the central risks.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	49.00K	49.00K	60.00K	0.00	110.00K	0.00
Gross Profit	49.00K	49.00K	-346.00K	-446.00K	70.00K	-430.19K
EBITDA	-3.16M	-3.16M	-2.78M	-6.89M	-9.29M	-4.77M
Net Income	-7.47M	-7.47M	-7.67M	-7.44M	-9.71M	-8.14M
Balance Sheet
Total Assets	2.74M	2.74M	8.97M	16.77M	25.27M	31.61M
Cash, Cash Equivalents and Short-Term Investments	1.72M	1.72M	5.92M	9.71M	14.22M	19.51M
Total Debt	0.00	0.00	0.00	6.00K	44.00K	84.00K
Total Liabilities	209.00K	209.00K	258.00K	591.00K	422.00K	1.11M
Stockholders Equity	2.53M	2.53M	8.71M	16.18M	24.85M	30.50M
Cash Flow
Free Cash Flow	-3.91M	-3.91M	-3.80M	-4.85M	-5.68M	-4.31M
Operating Cash Flow	-3.90M	-3.90M	-3.30M	-4.79M	-5.59M	-3.86M
Investing Cash Flow	-290.00K	-290.00K	-503.00K	1.89M	-98.00K	-149.00K
Financing Cash Flow	0.00	0.00	-6.00K	-1.60M	395.00K	21.78M

Mountain Valley MD Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.02
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:MVMD, the sentiment is Positive. The current price of 0.02 is above the 20-day moving average (MA) of 0.02, above the 50-day MA of 0.02, and below the 200-day MA of 0.02, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 51.89 is Neutral, neither overbought nor oversold. The STOCH value of 66.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:MVMD.

Mountain Valley MD Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PCLO	44 Neutral	C$13.85M	-2.51	―	―	15.64%	58.47%
LOBE	44 Neutral	C$16.17M	-2.86	―	―	-100.00%	-8.70%
RVV	43 Neutral	C$6.28M	-0.58	-664.21%	―	―	-80.42%
MVMD	41 Neutral	C$5.29M	-0.71	-148.48%	―	-46.59%	8.26%
CANB	41 Neutral	C$3.46M	-2.69	-11.42%	―	-5.87%	-239.53%
AYUR	40 Underperform	C$973.52K	-0.67	-271.33%	―	15.95%	-1.81%

Mountain Valley MD Corporate Events

Mountain Valley MD Details Year-End Commercialization Gains Across Core Platforms

Mountain Valley MD issued a year-end update highlighting commercialization progress across its three main platforms, with management emphasizing disciplined execution in product development, field validation and commercial foundations as the business enters a new growth phase. In nutraceuticals, the company is scaling its Quicksome™ technology through an exclusive U.S.-based GMP manufacturing partner, supporting ongoing production for Circadian Wellness’s Quicksome™-based Eons sublingual products and advancing new licensing opportunities in areas such as menopause symptom relief, muscle recovery, anti-inflammation and joint health, while preparing a fenugreek glycosides testosterone product launch via a licensee in the first half of 2026 and positioning its “Mountains Of…” branded line for either direct or white-label distribution; in agriculture, MVMD continues to validate and commercialize its Agrarius technology across diverse crops and regions, reinforcing its potential role in sustainable farming and laying a data-driven foundation for longer-term adoption.

The most recent analyst rating on (TSE:MVMD) stock is a Hold with a C$0.02 price target. To see the full list of analyst forecasts on Mountain Valley MD stock, see the TSE:MVMD Stock Forecast page.

Mountain Valley MD Advances Agrarius Product with Positive Trial Results

Mountain Valley MD has announced positive results from its Agrarius agricultural product trials in Brazil and Colombia, which are crucial for its commercialization strategy. The trials in Brazil showed significant improvements in citrus yield and plant health, particularly in reducing symptoms of citrus greening disease. In Colombia, the trials indicated enhanced pasture grass productivity and nutritional quality, suggesting potential benefits for the livestock sector. These findings support the company’s expansion objectives and highlight Agrarius as a promising tool for improving agricultural productivity and sustainability.